DCPH Deciphera Pharmaceuticals Inc.

29.91
+0.91  (+3%)
Previous Close 29
Open 28.98
Price To Book 3.64
Market Cap 1126446522
Shares 37,661,201
Volume 90,186
Short Ratio
Av. Daily Volume 265,527

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 update due 1Q 2019 est.
DCC-3014
Solid tumors or hematological malignancies
Phase 3 completion of enrolment announced November 15, 2018. Data due mid-2019.
DCC-2618 - INVICTUS
Gastrointestinal Stromal Tumors (GIST) - fourth-line
Phase 1 update at ESMO October 2018. ORR 21%, PFS 40 weeks - 2nd/3rd line.
DCC-2618
Gastrointestinal Stromal Tumors (GIST)
Phase 1 expansion data due 2019.
DCC-2618
Gastrointestinal Stromal Tumors (GIST)
Phase 3 trial initiation announced December 20, 2018.
DCC-2618 - INTRIGUE
Gastrointestinal Stromal Tumors (GIST) - second-line
Phase 1b trial complete.
Rebastinib
Breast Cancer
Phase 1b/2 trial initiation announced October 23, 2018.
Rebastinib
Solid tumors
Phase 1b/2 trial initiation announced January 3, 2019.
Rebastinib and carboplatin
Solid tumors

Latest News

  1. Deciphera Pharmaceuticals, Inc. to Present at the 1st Annual Guggenheim Healthcare Talks Idea Forum Oncology Day
  2. Deciphera Pharmaceuticals Shares March Higher, Can It Continue?
  3. Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today
  4. Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Carboplatin in Patients with Advanced or Metastatic Solid Tumors
  5. Deciphera Pharmaceuticals Announces Positive, Preliminary, Top-Line Clinical Data for the Ongoing Phase 1 Clinical Study with DCC-3014 and an Update on Future Development Plans
  6. Deciphera Pharmaceuticals, Inc. to Present at the 37th Annual J.P. Morgan Healthcare Conference
  7. Report: Developing Opportunities within AutoZone, Deciphera Pharmaceuticals, Clearwater Paper, Churchill Downs, Whitestone REIT, and ZTO Express (Cayman) — Future Expectations, Projections Moving into 2019
  8. Deciphera Pharmaceuticals Initiates Pivotal Phase 3 Clinical Study of Ripretinib (DCC-2618) in Second-line Patients with Gastrointestinal Stromal Tumors (“INTRIGUE” Study)
  9. Is Deciphera Pharmaceuticals, Inc. (DCPH) A Good Stock To Buy?
  10. Deciphera Pharmaceuticals, Inc. to Present at the 30th Annual Piper Jaffray Healthcare Conference
  11. Deciphera Pharmaceuticals Completes Enrollment in the INVICTUS Pivotal Phase 3 Clinical Study of DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors
  12. Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results
  13. Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Paclitaxel to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced or Metastatic Solid Tumors
  14. Deciphera Pharmaceuticals Reports Updated Preliminary Phase 1 Clinical Study Results with DCC-2618 at the European Society of Medical Oncology (ESMO) 2018 Congress
  15. Deciphera Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference
  16. Why Raymond James Is Bullish On Deciphera, Dova Pharmaceuticals
  17. Deciphera Pharmaceuticals, Inc. to Participate in Citi’s 13th Annual Biotech Conference